Publications by authors named "C O BETTS"
Article Synopsis
- * In a Phase II clinical trial, 27 patients received entinostat followed by nivolumab, resulting in an objective response rate of 11% and a median response duration of over 10 months, although the primary endpoint for overall effectiveness was not reached.
- * The combination treatment led to significant immune profile changes, including increased dendritic cell activity and enhanced inflammatory response, suggesting potential for improving treatment strategies in PDA despite
Article Synopsis
- - The SARS-CoV-2 virus, initially recognized as a respiratory virus, has been linked to various serious conditions beyond the lungs, including increased occurrences of strokes in otherwise healthy individuals, particularly due to its effect on the body’s coagulation system.
- - COVID-19 leads to a hypercoagulable state, causing both ischemic and hemorrhagic strokes that are often more severe and deadly, complicating treatment efforts in overwhelmed emergency departments.
- - This article reviews the rise in strokes during the COVID-19 pandemic, detailing their incidence, underlying mechanisms, symptoms, and the challenges of managing these cases, alongside discussions about vaccine safety in regard to stroke risk.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, emerged in December 2019, sparking a global health crisis. While initially recognized as a respiratory illness, it has become evident that Coronavirus disease 2019 (COVID-19) also affects the central nervous system. This comprehensive review focuses on the neurological manifestations of COVID-19 and its impact on patients with preexisting neurological disorders, particularly those with multiple sclerosis (MS) receiving disease-modifying therapies.
View Article and Find Full Text PDFA growing body of clinical and experimental evidence indicates that immune checkpoint blockade enhances patient susceptibility to hypersensitivity reactions to co-administered medications. In this study, we utilized an in vitro T-cell priming assay to demonstrate one of the mechanistic hypotheses on how this occurs; through lowering of the threshold in patients to elicit aberrant T-cell responses. We outline the dependency of de novo T-cell priming responses to drug-associated antigens on dose at initial exposure.
View Article and Find Full Text PDF